NASDAQ:CRIS Curis (CRIS) Stock Price, News & Analysis $0.48 0.00 (-0.88%) Closing price 04:00 PM EasternExtended Trading$0.48 +0.01 (+1.93%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Curis Stock (NASDAQ:CRIS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Curis alerts:Sign Up Key Stats Today's Range$0.47▼$0.5050-Day Range$0.48▼$1.0352-Week Range$0.46▼$3.13Volume160,141 shsAverage Volume292,964 shsMarket Capitalization$18.55 millionP/E RatioN/ADividend YieldN/APrice Target$17.00Consensus RatingHold Company Overview Curis, Inc. is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates. Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors. The company’s earlier success includes the development of vismodegib, marketed as Erivedge® through a collaboration and subsequent acquisition by Genentech, for the treatment of advanced basal cell carcinoma. Curis continues to pursue partnerships to advance its pipeline and leverage external expertise for product registration and commercialization. Founded in 1997 and headquartered in Lexington, Massachusetts, Curis operates research facilities in the greater Boston area and collaborates with academic institutions and industry partners worldwide. The company’s integrated discovery and development platform has been instrumental in generating therapeutic candidates across multiple cancer indications, with a strategic focus on precision medicines that offer the potential for improved patient outcomes and differentiated safety profiles. Curis is led by President and Chief Executive Officer Ali Fattaey, Ph.D., who joined the company in 2019 and brings extensive experience in oncology research and drug development. The senior management team comprises seasoned professionals in clinical development, regulatory affairs and commercial strategy, underscoring Curis’ commitment to advancing its pipeline candidates through critical regulatory milestones and toward potential market approval.AI Generated. May Contain Errors. Read More Curis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreCRIS MarketRank™: Curis scored higher than 52% of companies evaluated by MarketBeat, and ranked 481st out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingCuris has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialCuris has a consensus price target of $17.00, representing about 3,472.9% upside from its current price of $0.48.Amount of Analyst CoverageCuris has only been the subject of 2 research reports in the past 90 days.Read more about Curis' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Curis are expected to grow in the coming year, from ($1.27) to ($0.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Curis is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Curis is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCuris has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Curis' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.69% of the float of Curis has been sold short.Short Interest Ratio / Days to CoverCuris has a short interest ratio ("days to cover") of 0.48, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Curis has recently decreased by 1.25%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCuris does not currently pay a dividend.Dividend GrowthCuris does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment-0.56 News SentimentCuris has a news sentiment score of -0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Curis this week, compared to 2 articles on an average week.Search Interest4 people have searched for CRIS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows6 people have added Curis to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Curis insiders have not sold or bought any company stock.Percentage Held by Insiders5.42% of the stock of Curis is held by insiders.Percentage Held by Institutions29.97% of the stock of Curis is held by institutions.Read more about Curis' insider trading history. Receive CRIS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Curis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRIS Stock News HeadlinesCuris Inc. Earnings Call Highlights Clinical MomentumMay 13, 2026 | tipranks.comCuris anticipates TakeAim CLL initial 5-patient dosing by mid-2026 while projecting cash runway into second half of '27May 13, 2026 | seekingalpha.comNobody Understands Why Trump Is Invading Iran (here’s the answer)Most investors are reacting to the Iran strikes without understanding the underlying motive driving the decision. Addison Wiggin, Founder of Grey Swan Investment Fraternity, says there is a hidden reason behind the bombing - and knowing it could change how you position your money right now.May 19 at 1:00 AM | Banyan Hill Publishing (Ad)Curis Reaffirmed at Buy as Analyst Maintains $5 Price Target on Emavusertib Clinical Catalysts in CLL and PCNSLMay 13, 2026 | tipranks.comCuris Buy Rating Reiterated as Analyst Highlights Dual-Blockade Progress and Clinical Catalysts; $17 Price Target MaintainedMay 13, 2026 | tipranks.comCuris, Inc. (CRIS) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comCuris Provides First Quarter 2026 Business UpdateMay 12, 2026 | prnewswire.comCuris Q1 2026 earnings previewMay 12, 2026 | msn.comSee More Headlines CRIS Stock Analysis - Frequently Asked Questions How have CRIS shares performed this year? Curis' stock was trading at $0.9871 at the beginning of the year. Since then, CRIS stock has decreased by 51.8% and is now trading at $0.4758. How were Curis' earnings last quarter? Curis, Inc. (NASDAQ:CRIS) posted its quarterly earnings results on Tuesday, May, 12th. The biotechnology company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($0.33) by $0.92. Read the conference call transcript. When did Curis' stock split? Shares of Curis reverse split on Friday, September 29th 2023.The 1-20 reverse split was announced on Friday, September 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Curis' major shareholders? Top institutional investors of Curis include Renaissance Technologies LLC (0.92%) and Focused Wealth Management Inc (0.27%). View institutional ownership trends. How do I buy shares of Curis? Shares of CRIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Curis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Curis investors own include Micron Technology (MU), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), NIO (NIO), Sorrento Therapeutics (SRNE). Company Calendar Last Earnings5/12/2026Today5/19/2026AGM 20265/19/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CRIS's financial health is in the Red zone, according to TradeSmith. CRIS has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:CRIS CIK1108205 Webwww.curis.com Phone(617) 503-6500Fax617-503-6501Employees60Year Founded2000Price Target and Rating Average Price Target for Curis$17.00 High Price Target$17.00 Low Price Target$17.00 Potential Upside/Downside+3,472.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.58 million Net Margins-80.29% Pretax Margin-299.66% Return on EquityN/A Return on Assets-181.57% Debt Debt-to-Equity RatioN/A Current Ratio1.11 Quick Ratio1.11 Sales & Book Value Annual Sales$9.44 million Price / Sales1.96 Cash FlowN/A Price / Cash FlowN/A Book Value$0.33 per share Price / Book1.44Miscellaneous Outstanding Shares38,980,000Free Float36,866,000Market Cap$18.55 million OptionableNo Data Beta3.08 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:CRIS) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Curis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
